Accendra Health: Expansion opportunities will emerge later in 2026, accelerate in 2027

RICHMOND, Va. – Accendra Health reported net revenue of $613.2 million for the second quarter of 2026 vs. $681.9 million for same period last year. Other financial results:

• Loss from continuing operations, net of tax, GAAP: ($89.1 million) vs. ($83.8 million)
• Adjusted (loss) income from continuing operations, net of tax, non-GAAP: ($14.3 million) vs. $20.5 million
• Adjusted EBITDA, non-GAAP: $60.1 million vs. $96.6 million
• Free cash flow, non-GAAP: ($25.1 million) vs. $15.2 million
• Loss from continuing operations, net of tax, per common share, GAAP: ($1.16 million) vs. ($1.09 million)
• Adjusted (loss) income from continuing operations, net of tax, per common share, non-GAAP: ($0.19 million) vs. $0.26 million.

“Throughout the second quarter, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payer exit behind us,” said President and CEO Edward Pesicka. “In the last six months, we have eliminated well over $125 million of annualized operating expense directly associated with this large commercial payer, and we are now beginning to reset our business for accelerated future growth. Additionally, we reduced outstanding debt by $385 million and comprehensively reset our debt maturity profile through our balance sheet optimization transaction which closed in June.

“We also saw continued progress on key growth initiatives and new strategic partnerships that have both topline and bottom-line expansion opportunities that will begin to emerge in late 2026 and accelerate in 2027,” he continued. “These include the nationwide rollout of the Sleep Center of Excellence, new commercial agreements, and an increased emphasis on expense rationalization.”

Accendra Health is updating its prior financial guidance for full year 2026 to:

• Revenue: $2.45 billion - $2.55 billion
• Adjusted EBITDA: $300 million - $320 million
• Free cash flow: Breakeven to slightly positive

Related: Accendra Health lags in Q1 but lays groundwork for standalone status.